摘要
目的探讨RNA干扰切除修复交叉互补基因1(ERCC1)对肺癌细胞药物敏感性的影响。方法将肺癌A549/DDP细胞分为阴性组、空白组、ERCC1-shRNA1组及ERCC1-shRNA2组,通过不同方法检测分析ERCC1的mRNA和蛋白表达水平,及不同顺铂(DDP)浓度下肺癌细胞的凋亡程度。结果阴性组、空白组的ERCC1 mRNA及蛋白表达水平无显著差异(P>0.05);ERCC1-shRNA1组、ERCC1-shRNA2组的ERCC1 mRNA及蛋白表达水平与阴性组、空白组分别比较,差异均有统计学意义(P<0.05);ERCC1-shRNA1组、ERCC1-shRNA2组的ERCC1 mRNA及蛋白表达水平比较,差异无统计学意义(P>0.05)。ERCC1-shRNA 1组、阴性组、空白组的A549/DDP细胞抑制率均随着DDP浓度的升高而增加;DDP浓度为8、16、32μg/mL时,ERCC1-shRNA1组的A549/DDP细胞抑制率高于阴性组及空白组(P<0.05);阴性组、空白组的A549/DDP细胞抑制率比较,差异无统计学意义(P>0.05)。与0μg/mL相比,阴性组、空白组、ERCC1-shRNA 1组16、32μg/mL DDP的A549/DDP细胞凋亡率增加(P<0.05);DDP浓度为0、16、32μg/mL时,ERCC1-shRNA1组的A549/DDP凋亡率高于阴性组及空白组(P<0.05)。结论沉默ERCC1载体可减少肺癌A549/DDP细胞中ERCC1表达,可抑制肿瘤细胞增殖,增加化疗药物的敏感性。RNAi抑制交叉互补基因治疗肺癌患者的可行性高,能够为下一步临床工作提供理论基础。
Objective To investigate the effect of RNA interference of excision repair cross-complementation group 1(ERCC1)gene on drug sensitivity of lung cancer cells.Methods Lung cancer A549/DDP cells were divided into negative group,blank group,ERCC1-shRNA1 group and ERCC1-shRNA2 group.The mRNA and protein expression levels of ERCC1 and the degree of apoptosis of lung cancer cells under different cisplatin(DDP)concentrations were detected and analyzed by different methods.Results There were no significant differences in ERCC1 mRNA and protein expression levels between the negative group and the blank group(P>0.05);the ERCC1 mRNA and protein expression levels in the ERCC1-shRNA1 group and the ERCC1-shRNA2 group were compared with those in the negative group and the blank group,and the differences were statistically significant(P<0.05);there were no significant differences in ERCC1 mRNA and protein expression levels between the ERCC1-shRNA1 group and the ERCC1-shRNA2 group(P>0.05).The inhibition rates of A549/DDP cells in the ERCC1-shRNA1 group,the negative group and the blank group increased with the increase of DDP concentration;when DDP concentrations were 8,16 and 32μg/mL,the inhibition rate of A549/DDP cells in the ERCC1-shRNA1 group were higher than those in the negative group and the blank group(P<0.05);there was no significant difference in the inhibition rate of A549/DDP cells between the negative group and the blank group(P>0.05).Compared with 0μg/mL,the apoptosis rates of A549/DDP cells in 16 and 32μg/mL DDP of the negative group,the blank group and the ERCC1-shRNA1 group significantly increased(P<0.05);when DDP concentration were 0,16 and 32μg/mL,the apoptosis rates of A549/DDP in the ERCC1-shRNA1 group were higher than those in the negative group and the blank group(P<0.05).Conclusion Silencing ERCC1 vector can reduce the expression of ERCC1 in lung cancer A549/DDP cells,inhibit tumor cell proliferation and increase the sensitivity of chemotherapy drugs.RNAi inhibition of cross complementary gene therapy for lung cancer patients is highly feasible,which can provide a theoretical basis for further clinical work.
作者
邓淑娇
郑颖妮
DENG Shujiao;ZHENG Yingni(Hanzhong Central Hospital,Hanzhong 723000,China)
出处
《临床医学研究与实践》
2021年第4期9-12,共4页
Clinical Research and Practice
关键词
肺癌
RNA干扰
切除修复交叉互补基因1
药物敏感性
顺铂
lung cancer
RNA interference
excision repair cross-complementation group 1
drug sensitivity
cisplatin
作者简介
邓淑娇(1983-),女,汉族,湖南郴州人,主治医师,学士。研究方向:肺癌;通讯作者:郑颖妮,E-mail:yingni_01@163.com.
